热门资讯> 正文
Corcept寻求FDA批准用于卵巢癌治疗
2025-07-14 22:06
- Corcept Therapeutics (NASDAQ:CORT) has submitted a marketing application to the U.S. FDA for its cortisol modulator, Relacorilant, a drug designed to help patients with ovarian cancer that does not respond to platinum-based treatments.
- The application is supported by positive results from its recent studies.
- Stock is up 1%.
More on Corcept Therapeutics
- Beyond Cushing's: The Undervalued Potential Of Corcept's Cortisol Modulators
- Corcept: Remains A Strong Buy On Recent Weakness And Aggressive Sales Force Hiring
- Corcept Therapeutics Incorporated (CORT) Q1 2025 Earnings Call Transcript
- Corcept's mid-stage ALS study fails to meet main goal
- Corcept projects $900M-$950M revenue for 2025 amid advancing hypercortisolism treatments
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
